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Summary 
The efficacy of adjusted-dose oral anticoagulant treatment 
(OAT) in the prevention of stroke in atrial fibrillation (AF) is well 
documented. Available data show that AF patients are widely 
heterogeneous in terms of ischaemic stroke risk. The role of fe-
male gender as a predictor of stroke risk is inconsistent, in par-
ticular it is unclear if warfarin treatment is able to prevent stroke 
equally in both sexes. We performed a prospective study on 780 
AF patients on OAT, followed by an Anticoagulation Clinic, to 
evaluate if female gender is a risk factor for stroke among pa-
tients on OAT and if the quality of anticoagulation is different be-
tween genders. No difference was found in relation to the 
quality of anticoagulation between genders (p=0.5). During fol-
low-up 33 patients had major bleedings (rate 1.37x100 pt/yrs) 
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but no difference was found between genders in bleeding risk. 
Forty patients had ischaemic events [rate 1.66x100 pt/yrs; males 
rate 1.2 x100 pt/yrs; females rate 2.43x100 pt/yrs; p=0.042; 
relative risk (RR) of females vs. males 2.0 (95% confidence inter-
val [CI] 1.3–3.1); p= 0.004]. The higher rate of ischaemic events 
in females with respect to males was confirmed at Cox regres-
sion analysis after correction for age (p=0.009). In addition, 
strokes occurring in females were more disabling, and RR for se-
vere and fatal stroke, defined according to Modified Rankin 
scale, of females vs. males was 3.1 (95% CI 1.3–6.5; p=0.001). In 
conclusion, our data show a higher risk of stroke in anticoagu-
lated AF females with respect to males, despite a similar quality 
of anticoagulation. 
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Introduction 
Atrial fibrillation (AF) is associated with an increased risk of 
stroke and the efficacy of adjusted-dose warfarin treatment in the 
prevention of thrombotic complications of AF is well docu-
mented by trials published during the past 20 years (1). However, 
available data show that AF patients are widely heterogeneous in 
terms of ischaemic stroke risk, which ranges from 1–2% to 
12–18%/year (2). Because the net benefit of antithrombotic ther-
apy depends on the underlying risk of stroke, an accurate analysis 
of risk factors associated with stroke is needed to define the ap-
propriate antithrombotic strategy for the individual patient. Sev-
eral clinical characteristics have been investigated: age, hyperten-
sion, diabetes, heart failure, cardiac disease, history of previous 
stroke or transient ischamic attack (TIA) and gender. Published 
results are in agreement in indicating age, hypertension and his-
tory of previous stroke/TIA as good predictors of stroke risk 
whereas data about gender and other clinical characteristics of 
patients are contradictory (3). The Stroke Prevention in Atrial Fi-
brillation (SPAF) reported that women are at higher risk for is-
chaemic stroke (4). Similar results were found in other studies 
(5–6). However, several other authors did not confirm this find-
ing (7–11). A recent systematic review confirmed that this issue 
needs to be better clarified (6). Analysing non-anticoagulated AF 
patients, the AnTicoagulation and Risk factors In Atrial fibril-
lation (ATRIA) study found that women are at higher risk for 
stroke when off warfarin (12). However, when anticoagulation is 
started, warfarin appears to be as effective in women as in men. 
On the other hand, no study found a significant independent as-
sociation between gender and bleeding complications (13). 
Aim of our study was to evaluate in a cohort of AF patients 
prospectively followed up by an Anticoagulation Clinic if female 
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gender is a risk factor for stroke. In addition, since information 
about the quality of oral anticoagulant treatment (OAT) among 
females is scanty, we further investigated if the quality of antico-
agulation is different between genders and if this aspect could in-
fluence the risk of stroke. 
Methods 
Patients 
From June 1998 to December 2007, we prospectively investi-
gated 780 AF patients referred for the control of OAT to the Anti-
coagulation Clinic of the Azienda Ospedaliero-Universitaria Ca-
reggi, University of Florence. Methodology used for the enrol-
ment and follow-up has been previously described (14). Briefly, 
OAT indication was established according to American College 
of Chest Physicians (ACCP) (15) and Italian Federation of Anti-
coagulation Clinics (FCSA) guidelines (16).  
All patients were treated with warfarin and international nor-
malised ratio (INR) was maintained at the intended therapeutic 
range of 2–3. We calculated patient/years (pt/yrs) by our patients 
database. PARMA System 5.7 (17) was used and date of starting 
OAT and dates of all visits were recorded. Time of observation 
was calculated on consecutive periods of observation. When a pa-
tient left the Centre for more than two months this interval was ex-
cluded from the analysis and adverse events eventually occurred 
during this period were not included in the analysis. For the calcu-
lation of time in range, the Rosendaal method was used (18). 
Patients’ demographic and clinical data were collected. The 
presence of traditional cardiovascular risk factors and other char-
acteristics associated with ischaemic complications in AF was 
assessed on the basis of patients’ interview, echocardiography 
and hospital records.  
Follow-up visits were scheduled every 2–4 weeks for INR 
monitoring. Hospital admissions, concomitant therapies, inter-
current illnesses, bleeding and thrombotic events during follow-
up were recorded. Patients who missed check-ups for more than 
two months were contacted (personally or through their family or 
general practitioner) and the reason for interrupting treatment 
monitoring was recorded. In the case of death, further informa-
tion about its cause was requested. When this information was 
lacking, national register of causes of death and autopsy results 
(if available) were consulted. 
Outcomes 
Data were censored after the occurrence of TIA or stroke, major 
bleeding, after the cessation of OAT or when the patient stopped 
being monitored by our Anticoagulation Clinic. Stroke was de-
fined as a syndrome characterised by rapidly developing clinical 
symptoms and/or signs of focal and at times global loss of brain 
function, lasting > 24 hours, not explained by other causes and in 
the absence of primary haemorrhage. Ischaemic stroke was de-
fined as a stroke with either a normal brain computed to-
mography (CT) or evidence of a recent infarction in the clinically 
relevant area of the brain on a CT or magnetic resonance imaging 
(MRI) within three weeks of the event, while previous TIA was 
diagnosed when neurological defects lasted <24 hours. The 
Modified Rankin Disability Scale was used to measure func-
tional outcome 90 days after stroke (19). The diagnosis of TIA 
was accepted only if the event led to hospital admission and neur-
oradiologic imaging and neurologic evaluation were performed. 
Bleeding was classified as major when fatal, intracranial (docu-
mented by imaging), ocular causing blindness, articular, or retro-
peritoneal; when surgery or transfusion of more than two blood 
units were required or when haemoglobin was reduced of 2 g/dl 
or more. All cases of bleeding not classified as major were con-
sidered minor; clinically unrelevant bleedings were not recorded 
(20). When an ischaemic or bleeding event occurred, the INR re-
lated to the event was recorded. INR was defined as temporally 
related to the adverse event when it was obtained at the time of 
the event or during the preceding eight days. No patient was on 
hormonal replacement therapy. Finally, we applied to our pa-
tients CHADS2 score for stroke risk stratification (21). The use 
of aspirin in association to OAT was limited to patients with a re-
cent episode of acute coronary syndrome or when they had recur-
rent ischaemic episodes. Patients were instructed to avoid aspirin 
use and were routinely asked for it; aspirin use was recorded on 
electronic files.  
Statistical analysis 
Incidence rates for ischaemic and bleeding events were calculated 
as the number of events per 100 pt/yrs of observation (22). For this 
calculation observation started at the beginning of follow-up and 
ended when patients experienced an adverse event or were cen-
sored. The SPSS statistical software package (Statistical Package 
for Social Sciences, Chicago, IL, USA; software for Windows, ver-
sion 11.5) was used for data processing. Data are expressed as 
median and range due to their skewed distribution. Preliminary 
statistics were performed using Wilcoxon test. Statistical analysis 
Table 1: Clinical characteristics of patients and oral anticoagu-
lant treatment (OAT) quality. Bleeding and thrombotic events 
during OAT. 
 Males Females P-value 
Number (%)  505 (64.7) 275 (35.3)  
Follow-up (pt/yrs) 1544 862  
Median age (years)   74 (37–94)  76 (43–92) <0.001 
Chronic AF (%)  415 (82.2) 218 (80.4) 0.6 
Time spent in range (%)   70   71 0.4 
Time spent below range (%)   15  14 0.5 
Time spent above range (%)   14  15 0.6 
Mean warfarin 
dosage (mg) 
  25.2 ±12.2  22.7±10.6 0.02 
Major bleeding 
before starting OAT (%) 
  18 (3.6)   7 (2.5) 0.6 
Major bleeds 
(rate x 100 pt/yrs) 
  22 (1.4)  11 (1.3) 1.0 
Fatal bleeds 
(rate x 100 pt/yrs) 
   7 (0.5)   1 (0.1) 0.04 
Stroke/TIA 
(rate x 100 pt/yrs) 
 19 (1.2)  21 (2.4) 0.04 
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was performed using Fisher’s exact test (categorical data) and a 
p-value <0.05 was chosen for statistical significance. Univariate 
analysis was conducted to evaluate the independent risk factors for 
cerebral ischaemic events and a p-value <0.05 was chosen for stat-
istical significance. Multivariate regression model was constructed 
using age and variables showing a p-value <0.05 at univariate 
analysis. The independent effect of gender on the risk of ischaemic 
events on OAT was investigated by performing the incidence rate 
ratio (23) and a Cox regression analysis. 
Results 
Patients characteristics and OAT quality 
We performed a prospective study on 780 AF patients (505 
males, 275 females) for a total follow-up period of 2,406 pt/yrs. 
The characteristics of patients are listed in Table 1. Females were 
significantly older than men (p<0.001). Patients spent 14%, 71% 
and 15% of time below, within and above the intended thera-
peutic range, respectively; no difference was found in relation to 
the quality of anticoagulation between genders (Table 1). Mean 
warfarin dosage was significantly higher in men respect to 
women (p=0.02). During follow-up, 65 patients died (overall 
mortality rate 2.7 per 100 pt/yrs, 95% CI 0.5–5.1 ) including 52 
men (mortality rate of 3.4, 95% CI 0.7–5.6 and 1.5, 95% 
CI0.2–2.4 per 100 pt/yrs for men and women, respectively). 
Twenty-five patients (3.2%) had had an episode of major bleed-
ing before starting OAT (Table 1). 
Bleeding events during OAT 
Thirty-three patients had major bleeding (rate 1.37 per 100 pt/
yrs, 95% CI 0.1–2.1) (Table 1): 18 cerebral, 13 gastrointestinal, 
1 muscular haematoma, 1 haematuria. The INR value related to 
bleeding events was >4 in 4/33 patients (12%), 1/11 females 
(9%) and 3/22 males (14%) (p=1.0). Nine haemorrhages, eight 
cerebral, were fatal: seven in males, two in females (RR 2.2 – 
95% CI 1.0–4.3; p=0.04). Twenty-nine patients (3.7%) were also 
on treatment with aspirin 100 mg daily, 6/275 females (2.2%) 
and 23/505 (4.5%) (p=0.1). The rate of bleeding events between 
patients on and off aspirin treatment was similar (1.1 per 100 pt/
yrs vs 1.4 per 100 pt/yrs, p=1.0). 
Cerebral ischaemic events during OAT 
Forty patients had ischaemic events (rate 1.66 per 100 pt/yrs) in-
cluding 19 males (rate 1.2– 95% CI 0.7–2.4 per 100 pt/yrs) and 
21 females (rate 2.43– 95% CI 1.4–3.6 per 100 pt/yrs). The RR of 
females respect to males was 2.0 (95% CI 1.3–3.1); p< 0.01) 
(Table 1). Twenty-three were strokes (1 fatal), 13 were TIAs, four 
were peripheral emboli. No difference in the rate of tromboem-
bolic events was found in relation to the type of AF, chronic or 
paroxysmal (rate 1.5 per 100 pt/yrs vs 2.0 per 100 pt/yrs; p=0.3). 
The higher rate of thrombotic events in females respect to males 
was confirmed at Cox regression analysis after correction for 
age (hazard ratio [HR] 2.3; 95% CI 1.2–4.4; p<0.01). In addition 
strokes occurring in females were more disabling. By using 
Modified Rankin scale for severe and fatal (Rankin ≥3) stroke, 
8/13 women and 4/10 men had severe stroke (RR of females vs. 
males was 3.1; 95% CI 1.3–6.5; p<0.01). The INR value related 
to thromboembolic events was <2 in 20/40 patients (50%), 12/21 
females (57%) and 8/19 males (42%) (p=0.3). Classic risk fac-
tors for stroke and distribution of patients in relation to CHADS2 
score are reported in Table 2. When echocardiographic data were 
evaluated, the number of patients with enlargement of atria was 
Table 2: Baseline risk factors for stroke/TIA and CHADS2 strat-
ification of patients. 
Patients Males Females P-value 
Left ventricular dysfunction (%) 125 (32.0)  40 (19.6) 0.02 
Hypertension (%) 311 (62.1) 180 (66.2) 0.86 
Diabetes (%)  98 (19.7)  58 (21.3) 0.84 
Previous stroke/TIA (%) 139 (27.5)  89 (32.6) 0.34 
Peripheral artery disease (%)  83 (16.6)  27 (9.8) 0.01 
Dyslipidemia (%) 114 (24.6)  72 (28.5) 0.3 
Smoking habitus (%) 102 (21.7)  28 (10.9) <0.001 
Coronary artery disease (%) 131 (26.1)  33 (12.1) < 0.001 
CHADS2=1 107 (21.3)  61 (22.3) 0.9 
CHADS2=2 154 (30.5)  78 (28.5) 0.6 
CHADS2=3 105 (20.9)  67 (24.3) 0.8 
CHADS2=4  65 (12.9)  43 (15.7) 0.6 
CHADS2=5  18 (3.6)  16 (5.8) 0.1 
CHADS2=6   9 (1.8) - - 

















 CHADS2=0  47 (9.3)  10 (3.6) 0.8 
Table 3: Univariate analysis of risk factors for ischaemic events 
for patients on oral anticoagulant treatment (OAT). 
 OR 95% CI P-value 
Previous stroke/TIA 7.1 3.51–14.05 <0.001 
Hypertension 2.3 1.05–5.08 0.03 
Female gender 2.1 1.12–4.01 0.02 
Age 1.0 0.98–1.07 0.3 
Diabetes 1.4 0.65–2.84 0.4 
Left ventricular dysfunction 1.0 0.43–2.29 0.1 
Coronary artery disease 0.5 0.20–1.39 0.2 










Table 4: Multivariate analysis of risk factors for ischaemic 
events for patients on oral anticoagulant treatment (OAT) ad-
justed for age. 
 OR 95% CI P-value 
Previous stroke/TIA 7.7 3.61–16.31 <0.001 
Hypertension 3.9 1.75–8.55 0.001 
Female gender 2.9 1.46–5.63 0.002 
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similar in the two genders (68% females, 69% males; p=0.9) and 
in relation to the occurrence of stroke (p=0.1). Univariate analy-
sis showed that history of previous ischaemic event, hyperten-
sion and female gender are significantly associated with the oc-
currence of cerebral ischaemic events during OAT (Table 3). 
A multivariate analysis adjusted for age, gender, previous is-
chaemic event, hypertension, confirmed that previous ischaemic 
event, hypertension and female gender are independent risk fac-
tors for the occurrence of embolic events during OAT (Table 4). 
Discussion 
Our cohort of AF patients shows a prevalence of women of 
35.3%, consistent to other studies. Indeed, the majority of studies 
published to date have concluded that AF is more prevalent in 
men than in women (3), with a rate of females ranging from 28% 
(4) to 42% (12). 
In our patients on chronic warfarin treatment, women had 
higher risk of ischaemic stroke than men. Among women higher 
rates of thromboembolic events were not related to age or to the 
presence of classic stroke risk factors. It is known that patients 
treated with warfarin suffer from less severe stroke than patients 
off warfarin (24). However, in our cohort women on warfarin ex-
perienced more severe and disabling strokes than men, suggest-
ing that OAT provide a lower protection than in men. It should be 
noted that the quality of anticoagulation was similar in the two 
genders, ruling out that the occurrence of thromboembolic 
events was due to a poor quality of the therapy. The ATRIA Study 
(12), analysing AF patients not on OAT, reported a higher rate of 
stroke among females, suggesting that women carry an intrinsic 
higher risk of stroke. Similarly, a higher rate of stroke among 
women was found in the cohort of Framingham study (5) and 
among women on aspirin or aspirin plus fixed, low-dose warfa-
rin treatment in data-set of SPAFI-III studies (4). In our popu-
lation, that included only patients on OAT, we confirmed that 
stroke risk in females remains higher than in men even when re-
duced by warfarin treatment. Pengo et al. (25), analysing a simi-
lar cohort of AF patients on OAT, did not find higher rate of 
stroke among females. However, the total follow-up period of 
this study was shorter than our and only one ischaemic stroke 
was recorded. Conversely, the analysis of SPORTIF (26) trials 
found a higher stroke risk among women on OAT, but the statis-
tical power of the study referring specifically data involving 
women was limited. The higher rate of stroke among females in 
our cohort could not be related to the presence of another possi-
ble favouring factor such as estrogen replacement therapy, be-
cause this practice is rarely used in elderly women in our country 
and none of our patients was on this treatment. 
In our population, as expected, the presence of coronary ar-
tery disease was significantly higher among men with respect to 
women. Similarly, also left ventricular dysfunction, probably as 
a consequence of coronary arteriopathy, and peripheral arterio-
pathy were more frequent in men. Coronary and peripheral ar-
tery disease are both part of atherotrombotic vascular disease, 
that is associated with high stroke risk. Nevertheless, according 
to the probable cardioembolic origin of ischaemic events rec-
orded, stroke is more frequent among women that are less af-
fected by atherothrombosis. The difference in the rate of throm-
boembolism between women and men seems not related to the 
contemporary aspirin therapy. Actually, the use of antiplatelet 
therapy in our cohort was limited to a small number of patients 
and not significantly different among genders. Other authors (5) 
hypothesised that the different atrial structure in women could 
influence the different thromboembolic risk. However, in our 
group the number of patients with enlargement of atria at trans-
thoracic echocardiography was similar between genders. 
Our data confirmed that the history of previous stroke/TIA is 
an independent risk factor for stroke, with an OR 7.7 (27). Hy-
pertension was also confirmed as a risk factor for stroke with an 
increase of risk of about two folds. In our study the presence of 
diabetes mellitus was not a significantly independent risk factor 
for stroke, in agreement with other studies (8, 9, 11, 28). 
We confirmed that bleeding risk in AF patients is similar be-
tween genders (12–13) and we observed a low rate of bleeding 
events, in agreement with previous observations obtained in patients 
followed by devoted agencies (24, 25, 28, 29). The Anticoagulation 
Clinics usually provide better OAT quality control and a lower war-
farin related bleeding rate (29–30). There is wide evidence that elev-
ated INR levels are related with bleeding risk (20, 31–33). Instead, 
the relation between INR<2 and increased stroke risk has been re-
ported (34), but when the analysis was extended to the quality of 
OAT over time, this relation seemed less clear (24, 35). 
Limitations of the study 
A limitation of the study is that it was conducted in a single 
centre were patients are intensively followed for OAT manage-
What is known about this topic? 
− The efficacy of adjusted-dose oral anticoagulant treat-
ment (OAT) in the prevention of stroke in atrial fibril-
lation (AF) is well documented and an accurate stratifi-
cation of patients’ risk is needed to choose the appropri-
ate antithrombotic strategy. 
− Published results are in agreement in indicating age, hy-
pertension and history of previous stroke/TIA as good 
predictors of stroke risk; whereas the evidence about 
gender and other clinical characteristics of patients is less 
convincing. Actually, the analysis of published data on fe-
male gender as a risk factor for stroke in AF patients gave 
contradictory results.  
What does this paper add? 
− In this paper we evaluate in a cohort of AF patients (pros-
pectively followed by an anticoagulation clinic) if female 
gender is a risk factor for stroke and if the quality of anti-
coagulation is different between genders.  
− In the literature, there is no information about the quality 
of OAT among females and if this aspect could influence 
the risk of stroke. Our data show a higher stroke risk in 
females with respect to males, despite a similar quality of 
anticoagulation. Bleeding risk of women on OAT was not 
different from men, and women were less likely than men 
to develop cerebral bleeding.
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ment reaching a good quality of OAT. Therefore, the number of 
cerebral ischaemic events recorded is limited. 
Conclusions 
In conclusion, our data indicate a higher risk of stroke in females 
with respect to males, despite a similar quality of anticoagu-
lation. This finding was independent of age and of the presence 
of other risk factors for stroke, supporting the use of anticoagu-
lant therapy in females. Overall, we found no difference in bleed-
ing risk by gender. Our data suggest that men may be at higher 
risk for cerebral bleeding. However, the number of events was 
too small for definitive conclusion and this finding warrants 
further investigation. 
